(NASDAQ:LXRX), FDA End-of-Phase 2 meeting for pilavapadin in DPNP to be held by year-end All IND-enabling studies of LX9851 for obesity completed and submitted to licensee Novo Nordisk Site initiation for SONATA-HCM Phase 3 study of sotagliflozin in both obstructive and non-obstructive HCM completed; enrollment completion on target for 2026 Additional data in support of […]
(NASDAQ:KELYA),(NASDAQ:KELYB), TROY, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced results for the third quarter of 2025. Q3 revenue of $935.0 million, down 9.9% year-over-year; excluding discrete U.S. federal government and large customer impacts, underlying revenue down approximately 2.0% year-over-year Underlying revenue reflects continued
(TSX:GUD), Achieved record-high quarterly revenues, Adjusted EBITDA1 and Adjusted EBITDA per share1 since inception Increased 2025 financial guidance MONTREAL, Nov. 06, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2025. All currency amounts
(NASDAQ:PVLA), WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen,
(NYSE:DTC),(Pinksheets:DTCB),(PinkSheets:DTCB),(NYSE:SBDS), GRAPEVINE, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) — Solo Brands, Inc. (NYSE: SBDS)(1) (“Solo Brands” or “the Company”) a leading portfolio of lifestyle brands (Solo Stove, Chubbies, Isle and Oru) that are redefining the outdoor and apparel industries, today announced its financial results for the three and nine months ended September 30, 2025. “The
(NasdaqGM:MCFT), VONORE, Tenn., Nov. 06, 2025 (GLOBE NEWSWIRE) — MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT) today announced financial results for its fiscal 2026 first quarter ended September 28, 2025. The overview, commentary, and results provided herein relate to our continuing operations, which consists of our MasterCraft and Pontoon segments. Overview: Net sales for the first
(NASDAQ:NCNO),(NASDAQ:EBC), WILMINGTON, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), the leading provider of intelligent, best-in-class banking solutions, today announced that Eastern Bank has expanded its loan origination and operations platform with nCino, selecting the Company's Consumer Banking and Mortgage solutions to complement its existing Commercial Banking Solution, creating a connected lending
(NASDAQ:PSTV), HOUSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces its participation at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting, Melanoma Research Foundation (MRF) Brain Metastases Summit 4.0 on
(NASDAQ:CGTX), – $30 Million Registered Direct Offering Support Next Stage of Development for Zervimesine (CT1812) – – Aligned with U.S. FDA on Registrational Path for Zervimesine – – Expanded Access Program for Dementia with Lewy Bodies Ongoing – PURCHASE, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX),
(NASDAQ:MTSI), LOWELL, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI), a leading supplier of semiconductor products, today announced its financial results for its fiscal fourth quarter and fiscal year ended October 3, 2025. Fourth Quarter Fiscal Year 2025 GAAP Results Revenue was $261.2 million, an increase of 30.1%,